Antioxidant treatment ameliorates prefrontal hypomyelination and cognitive deficits in a rat model of schizophrenia

Keyphrases

• Cognitive Deficits 100%
• Schizophrenia 100%
• Rat Model 100%
• Hypomyelination 100%
• Antioxidant Therapy 100%
• Schizophrenia Models 100%
• MRNA Expression 66%
• Medial Prefrontal Cortex (mPFC) 66%
• Cognitive Dysfunction 66%
• Prefrontal Cortex 66%
• Mitochondria 66%
• N-acetylcysteine 66%
• Cognitive Impairment 33%
• Postnatal Day 33%
• Oxidative Stress 33%
• Cognitive Symptoms 33%
• Myelin 33%
• Postnatal Development 33%
• Glutathione Level 33%
• Chronic Treatment 33%
• Antioxidant 33%
• Interneuron 33%
• Reduced Glutathione 33%
• Blood Glutathione 33%
• RNA Sequencing (RNA-seq) 33%
• Differentially Expressed Pathways 33%
• Lineage Progression 33%
• Oligodendrocyte Lineage 33%
• Neurodevelopmental Abnormalities 33%
• Glutathione Precursor 33%
• Antioxidant Gene Expression 33%
• Antioxidant Metabolism 33%

Neuroscience

• Cognitive Disorders 100%
• Antioxidant 100%
• Glutathione 60%
• Prefrontal Cortex 40%
• Mitochondrion 40%
• Acetylcysteine 40%
• Messenger RNA 40%
• Oxidative Stress 20%
• Metabolic Pathway 20%
• Gene Expression 20%
• Myelin 20%
• RNA Sequence 20%
• Oligodendrocyte 20%
• Interneuron 20%

INIS

• rats 100%
• antioxidants 100%
• glutathione 60%
• levels 40%
• mitochondria 40%
• messenger-rna 40%
• therapy 20%
• symptoms 20%
• blood 20%
• rna 20%
• genes 20%
• metabolism 20%
• precursor 20%
• oxidation 20%
• myelin 20%